Key Takeaways:
Becton, Dickinson and Co. shares rose 5.7% after the medical device maker reported second-quarter results that topped estimates and raised its full-year profit forecast, signaling its more focused strategy following a major business spinoff is delivering growth.
"We delivered a solid second quarter, with revenue, margins and EPS all ahead of our expectations," Tom Polen, chairman, CEO and president of BD, said in a statement. "Based on our first‑half performance and improved visibility into the balance of the year, we are raising our full‑year adjusted EPS guidance."
The Franklin Lakes, New Jersey-based company posted revenue of $4.71 billion for the three months ended March 31, a 5.2% increase from the prior year and ahead of the $4.67 billion consensus. Adjusted earnings per share came in at $2.90, beating analyst expectations by 13 cents. Growth was led by its Interventional segment, which saw revenues climb 7.3 percent.
The performance provides an early validation of the company's strategy to streamline its operations, having recently completed the separation of its Biosciences & Diagnostic Solutions business. With its full-year adjusted EPS guidance now lifted to a range of $12.52 to $12.72, investors are watching to see if the renewed focus can generate sustained momentum. The company also solidified its leadership, naming 25-year company veteran Vitor Roque as its permanent chief financial officer.
The appointment of Vitor Roque, who had served as interim CFO for about six months, brings stability to the company's financial leadership at a pivotal time. "After more than two decades with the company, I see tremendous opportunity ahead – with a clear, well‑defined strategy to unlock significant growth," Roque said.
The strong quarter, the first since the spinoff, suggests the remaining, more streamlined portfolio of medical devices and systems is performing well. Growth was broad-based across its four segments, with Interventional (7.3%), Connected Care (4.9%), Medical Essentials (4.7%), and BioPharma Systems (2.5%) all contributing to the top-line beat. The results may give analysts reason to revisit their models, with the median 12-month price target from 13 analysts currently standing at $180, according to data from Quiver Quantitative.
This article is for informational purposes only and does not constitute investment advice.
